12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Androxal enclomiphene regulatory update

Repros modified an SPA for 2 planned Phase III trials with oral Androxal enclomiphene to treat secondary hypogonadism to include additional secondary endpoints specifying the number of men...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >